Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA

被引：0
|
作者：
Joseph P. Garay
Rebecca Smith
Kaylyn Devlin
Daniel P. Hollern
Tiera Liby
Moqing Liu
Shanta Boddapati
Spencer S. Watson
Amanda Esch
Ting Zheng
Wallace Thompson
Darcie Babcock
Sunjong Kwon
Koei Chin
Laura Heiser
Joe W. Gray
James E. Korkola
机构：
[1] Oregon Health & Science University,Department of Biomedical Engineering
[2] University of North Carolina,Department of Genetics
[3] Chapel Hill,undefined
来源：
Breast Cancer Research | / 23卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA
    Garay, Joseph P.
    Smith, Rebecca
    Devlin, Kaylyn
    Hollern, Daniel P.
    Liby, Tiera
    Liu, Moqing
    Boddapati, Shanta
    Watson, Spencer S.
    Esch, Amanda
    Zheng, Ting
    Thompson, Wallace
    Babcock, Darcie
    Kwon, Sunjong
    Chin, Koei
    Heiser, Laura
    Gray, Joe W.
    Korkola, James E.
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [2] Sensitivity to lapatinib differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA and relies on production of PIP3
    Garay, J. P.
    Korkola, J. E.
    Gray, J. W.
    CANCER RESEARCH, 2017, 77
  • [3] Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
    Kataoka, Y.
    Mukohara, T.
    Shimada, H.
    Saijo, N.
    Hirai, M.
    Minami, H.
    ANNALS OF ONCOLOGY, 2010, 21 (02) : 255 - 262
  • [4] Helical and kinase domain mutations of PIK3CA, and their association with hormone receptor expression in breast cancer
    Vatte, Chittibabu
    Al Amri, Ali Mohammed
    Cyrus, Cyril
    Chathoth, Shahanas
    Alsayyah, Ahmed
    Ahmad, Arafat
    Akhtar, Mohammed Shakil
    Alrashidi, Nada Fehaid
    Jayaseeli, Nithya
    Al Wadani, Hamed
    Al Zahrani, Alhussain
    Al Ali, Amein Kadhem
    ONCOLOGY LETTERS, 2019, 18 (03) : 2427 - 2433
  • [5] PI3K inhibitors overcome resistance to HER2-targeted agents caused by PIK3CA mutations in HER2-amplified breast cancer cell lines
    Kataoka, Yu
    Minami, Hironobu
    Shimada, Hiroyuki
    Saijo, Nagahiro
    Hirai, Midori
    Mukohara, Toru
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [6] A central role for HER3 in HER2-amplified breast cancer:: implications for targeted therapy
    Lee-Hoeflich, Si Tuen
    Crocker, Lisa
    Yao, Evelyn
    Pham, Thinh
    Munroe, Xander
    Hoeflich, Klaus P.
    Sliwkowski, Mark X.
    Stern, Howard M.
    CANCER RESEARCH, 2008, 68 (14) : 5878 - 5887
  • [7] PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum
    Goel, S.
    Krop, I. E.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1368 - 1372
  • [8] PIK3CA Mutation Is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients
    Kim, Ju Won
    Lim, Ah Reum
    You, Ji Young
    Lee, Jung Hyun
    Song, Sung Eun
    Lee, Nam Kwon
    Jung, Seung Pil
    Cho, Kyu Ran
    Kim, Cheol Yong
    Park, Kyong Hwa
    CANCER RESEARCH AND TREATMENT, 2023, 55 (02): : 531 - 541
  • [9] Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas
    Barbareschi, Mattia
    Buttitta, Fiamma
    Felicioni, Lara
    Cotrupi, Sabrina
    Barassi, Fabio
    Del Grammastro, Maela
    Ferro, Antonella
    Palma, Paolo Dalla
    Galligioni, Enzo
    Marchetti, Antonio
    CLINICAL CANCER RESEARCH, 2007, 13 (20) : 6064 - 6069
  • [10] Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?
    Amatu, Alessio
    Bencardino, Katia
    Sartore-Bianchi, Andrea
    Siena, Salvatore
    ANNALS OF TRANSLATIONAL MEDICINE, 2013, 1 (02)
12345